Oppenheimer & Co. Inc. Trims Stock Position in Bionano Genomics, Inc. (NASDAQ:BNGO)

Oppenheimer & Co. Inc. cut its stake in shares of Bionano Genomics, Inc. (NASDAQ:BNGOGet Rating) by 42.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 37,966 shares of the company’s stock after selling 28,216 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Bionano Genomics were worth $52,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of BNGO. Gerber Kawasaki Wealth & Investment Management purchased a new position in Bionano Genomics during the second quarter valued at approximately $27,000. Merit Financial Group LLC purchased a new position in Bionano Genomics during the first quarter valued at approximately $28,000. Freestone Capital Holdings LLC purchased a new position in Bionano Genomics in the first quarter worth $29,000. Washington Trust Bank grew its holdings in Bionano Genomics by 49.3% in the second quarter. Washington Trust Bank now owns 20,900 shares of the company’s stock worth $29,000 after purchasing an additional 6,900 shares during the last quarter. Finally, Magnus Financial Group LLC purchased a new position in Bionano Genomics in the first quarter worth $33,000. 28.44% of the stock is owned by hedge funds and other institutional investors.

Bionano Genomics Price Performance

NASDAQ BNGO opened at $2.47 on Monday. The firm’s fifty day simple moving average is $2.20 and its two-hundred day simple moving average is $2.02. The company has a current ratio of 6.51, a quick ratio of 5.77 and a debt-to-equity ratio of 0.01. Bionano Genomics, Inc. has a 12-month low of $1.16 and a 12-month high of $4.56. The firm has a market capitalization of $733.40 million, a P/E ratio of -6.02 and a beta of 2.25.

Bionano Genomics (NASDAQ:BNGOGet Rating) last released its quarterly earnings results on Thursday, November 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.01. Bionano Genomics had a negative net margin of 451.42% and a negative return on equity of 38.48%. The business had revenue of $7.22 million for the quarter, compared to analyst estimates of $6.70 million. Analysts forecast that Bionano Genomics, Inc. will post -0.39 EPS for the current fiscal year.

About Bionano Genomics

(Get Rating)

Bionano Genomics, Inc provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight.

Further Reading

Want to see what other hedge funds are holding BNGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bionano Genomics, Inc. (NASDAQ:BNGOGet Rating).

Institutional Ownership by Quarter for Bionano Genomics (NASDAQ:BNGO)

Receive News & Ratings for Bionano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.